Literature DB >> 25232428

Quadruple test parameters in art pregnancies.

Nilgün Güdücü1, Uzay Görmüş2, Ebru İlhan Güner3, Omer Güzel3, Zehra Neşe Kavak4.   

Abstract

AIM: Quadruple test is used for Down's syndrome screening in the second trimester of pregnancy. The aim of this study was to investigate differences in quadruple test parameters between pregnancies achieved by assisted reproductive treatments (ART) and spontaneous conception.
MATERIALS AND METHODS: We retrospectively compared levels of alfa-fetoprotein (AFP), unconjugated Estriol (uE3), inhibin-A and hCG and also screen positive test results.
RESULTS: Levels of all quadruple test parameters were statistically significantly increased in ART pregnancies when compared to spontaneous pregnancies, AFP was 1.4±0.74 and 1.16±0.53, (p=0.001), uE3 was 1.10±0.37 and 1.00±0.28, (p=0.004), hCG was 1.56±1.04 and 1.26±0.76, (p=0.001), inhibin A was 1.38±0.76 and 1.08±0.57, (p=0.001), screen positive tests were nearly doubled (4.8% and 8.4%).
CONCLUSIONS: Increased screen positive test results and quadruple test parameters in ART pregnancies may lead to unnecessary amniocentesis.

Entities:  

Keywords:  AFP; ART; estriol; hCG; inhibin-A; quadruple test

Year:  2014        PMID: 25232428      PMCID: PMC4161588     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  31 in total

1.  Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons.

Authors:  R Maymon; A Shulman
Journal:  Hum Reprod       Date:  2002-04       Impact factor: 6.918

2.  Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies.

Authors:  R Maymon; A Shulman
Journal:  Hum Reprod       Date:  2001-04       Impact factor: 6.918

3.  Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome.

Authors:  R Räty; A Virtanen; P Koskinen; L Anttila; J Forsström; P Laitinen; P Mörsky; A Tiitinen; U Ekblad
Journal:  Hum Reprod       Date:  2002-02       Impact factor: 6.918

4.  Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies.

Authors:  Jennifer D Rice; Sarah F McIntosh; Anne C Halstead
Journal:  Prenat Diagn       Date:  2005-03       Impact factor: 3.050

5.  Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy.

Authors:  S Holding; H Cuckle
Journal:  Prenat Diagn       Date:  1994-04       Impact factor: 3.050

6.  Down's syndrome screening marker levels following assisted reproduction.

Authors:  G Barkai; B Goldman; L Ries; R Chaki; J Dor; H Cuckle
Journal:  Prenat Diagn       Date:  1996-12       Impact factor: 3.050

7.  Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction.

Authors:  A Perheentupa; A Ruokonen; L Tuomivaara; M Ryynänen; H Martikainen
Journal:  Hum Reprod       Date:  2002-03       Impact factor: 6.918

Review 8.  Intra-ovarian roles of activins and inhibins.

Authors:  Phil G Knight; Leanne Satchell; Claire Glister
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

9.  First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI.

Authors:  A C Gjerris; A Loft; A Pinborg; M Christiansen; A Tabor
Journal:  Ultrasound Obstet Gynecol       Date:  2009-01       Impact factor: 7.299

10.  Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome.

Authors:  Françoise Muller; Sophie Dreux; Alain Lemeur; Corinne Sault; Jean Desgrès; Marguerite-Anne Bernard; Claude Giorgetti; Catherine Lemay; Sophie Mirallié; Alain Beauchet
Journal:  Prenat Diagn       Date:  2003-12-30       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.